ArticleThe British journal of ophthalmology2014
A novel classification of the vascular patterns of polypoidal choroidal vasculopathy and its relation to clinical outcomes.
Article in The British journal of ophthalmology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 77 citations in OpenAlex.
- EVEREST study report 4: Fluorescein angiography features predictive of polypoidal choroidal vasculopathy.Clinical & experimental ophthalmology · 2019Trial
- EVEREST study report 3: diagnostic challenges of polypoidal choroidal vasculopathy. Lessons learnt from screening failures in the EVEREST study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2016Trial
- EVEREST study report 2: imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathy.The British journal of ophthalmology · 2015Trial
- Combined Therapy Versus Fortified Anti-VEGF Monotherapy in Type C Polypoidal Choroidal Vasculopathy: Long-Term Outcomes and Exploratory Biomarker Insights.International journal of molecular sciences · 2026Article
- Review on classification of polypoidal choroidal vasculopathy.International ophthalmology · 2024Review
- Characteristics and treatment response of polypoidal choroidal vasculopathy in highly myopic eyes.Eye (London, England) · 2023Article
- Clinical variations of polypoidal choroidal vasculopathy: A cohort study from Japan and the USA.Scientific reports · 2023Article
- Different Morphology of Branching Neovascular Network in Polypoidal Choroidal Vasculopathy: A Swept-Source Optical Coherence Tomography Angiography Study.Journal of clinical medicine · 2023Article
- Polypoidal Choroidal Vasculopathy: An Update on Diagnosis and Treatment.Clinical ophthalmology (Auckland, N.Z.) · 2023Review
- Evolution of Polypoidal Lesions after Treatment of Polypoidal Choroidal Vasculopathy.Ophthalmology science · 2022Article
- Optical coherence tomography in diagnosing polypoidal choroidal vasculopathy. Looking into the future: a systematic review and meta-analysis.International journal of retina and vitreous · 2022Review
- Clinical features and prognosis of polypoidal choroidal vasculopathy with different morphologies of branching vascular network on optical coherence tomography angiography.Scientific reports · 2021Article
- Comparison of Polypoidal Choroidal Vasculopathy Lesion Sizes Measured on Multicolor Imaging and Indocyanine Green Angiography.Translational vision science & technology · 2021Article
- Idiopathic polypoidal choroidal vasculopathy: a review of literature with clinical update on current management practices.International ophthalmology · 2021Review
- Comparison of visual outcomes between therapy choices and subtypes of polypoidal choroidal vasculopathy (PCV) in Taiwan: a real-world study.Scientific reports · 2021Article
- Polypoidal Choroidal Vasculopathy Diagnosis and Neovascular Activity Evaluation Using Optical Coherence Tomography Angiography.BioMed research international · 2021Observational
- Impact of sub-foveal choroidal thickness on clinical features and long-term clinical outcomes in polypoidal choroidal vasculopathy.International ophthalmology · 2021Observational
- Predictors of persistent disease activity following anti-VEGF loading dose for nAMD patients in Singapore: the DIALS study.BMC ophthalmology · 2020Article
- The association of polypoidal choroidal vasculopathy clinical phenotypes with previously reported genetic markers.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2020Article
- Association between pachychoroid and long-term treatment outcomes of photodynamic therapy with intravitreal ranibizumab for polypoidal choroidal vasculopathy.Scientific reports · 2020Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo propose a novel classification system for polypoidal choroidal vasculopathy (PCV), and compare the clinical outcomes among PCV subtypes.
methodsConsecutive treatment-naive patients with symptomatic PCV were managed over 5 years. PCV subtypes were classified based on indocyanine green angiography (ICGA) and fluorescein angiography (FA) characteristics.
resultsAmong 107 patients, 3 PCV subtypes were seen: Type A (interconnecting channels on ICGA) -22.4%; Type B (branching vascular network with no leakage) -24.3%; Type C (branching vascular network with late leakage on FA) -53.3%. The proportion of patients with best-corrected visual acuity (BCVA) ≥20/40 was highest in Type A, intermediate in Type B and lowest in Type C at all time points (80% vs 66.7% vs 7.7% at 5 years, p<0.001). The highest rate of moderate visual loss (loss of ≥3 lines) occurred in Type C PCV (57.7% vs 0% for Types B and A at 5 years, p<0.001). Risk factors for poor visual outcomes were PCV subtype (OR 53.7, p<0.001 for Type C and OR 13.7, p=0.023 for Type B compared to Type A) and age (OR 1.06, 95% CI 1.002 to 1.125, p=0.044).
conclusionsThe PCV subtype seen on initial presentation affects the long-term visual outcomes over a 5-year period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.